乙醛脱氢酶在乳酸乳球菌中的表达与纯化

目的:在乳酸乳球菌中重组表达乙醛脱氢酶(ALDH)。方法:合成毕赤酵母ALDH基因,PCR扩增后通过重组构建pNZ8048-ALDH表达载体,电转至乳酸乳球菌NZ9000感受态,Nisin诱导表达后经Ni柱亲和层析纯化ALDH蛋白,比色法测定酶活。结果:构建了pNZ8048-ALDH表达载体,在乳酸乳球菌NZ9000中实现了ALDH的重组表达,目的蛋白占全菌蛋白的17.2%,其中可溶性表达比例为53%,重组菌株ALDH活力为0.638 U/mL,亲和层析纯化蛋白纯度约70%,比活为0.48 U/mg。结论:在乳酸乳球菌中表达并纯化获得了有活性的ALDH。     

表达猪传染性胃肠炎病毒S蛋白重组乳酸乳球菌在模拟动物胃肠道内的稳定性检测

为确定本实验室研究构建的表达猪传染性胃肠炎病毒S蛋白重组乳酸乳球菌pNZ8112-Sa/NZ9000在模拟动物肠道内稳定性,对重组菌株的培养条件、蛋白表达和质粒携带以及在模拟胃肠道环境中的稳定性进行了检测。实验结果表明能够保持其蛋白表达的稳定性及重组质粒的稳定性;模拟胃肠道环境实验结果表明重组菌能够耐受胰蛋白酶溶液、0.1%的胆汁及在含有胃蛋白酶pH 1.5的盐酸存活1 h和在pH 2.5的盐酸耐受性良好。     

猪传染性胃肠炎病毒S蛋白在乳酸菌中的表达

目的：构建猪传染性胃肠炎病毒S蛋白的细胞内表达重组乳酸乳球菌,确定其最佳表达条件,为重组乳酸菌作为口服疫苗防治猪传染性胃肠炎奠定基础。方法：根据猪传染性胃肠炎病毒纤突（S）蛋白的全基因序列及表达载体质粒的基因融合特点,设计一对引物,进行PCR,获得含有TGEV S基因4个主要抗原位点的约2000bp目的片段,将其与表达载体质粒pNZ8048进行连接,通过电转化进入宿主菌乳酸乳球菌NZ9000细胞内,在乳链菌肽（Nisin）的诱导下进行表达,确定最佳表达条件;并通过SDS-PAGE进行检测和Western-blot分析表达蛋白活性。结果：成功获得了TGEV S蛋白在乳酸乳球菌细胞内的表达并且表达的蛋白具有TGE全病毒的抗原性。确定了乳酸乳球菌表达TGEV S蛋白的最佳表达条件为在以1ng/ml的乳链杆菌肽nisin诱导下,诱导后3h,重组蛋白表达效率达最高,重组蛋白约占菌体总蛋白含量的8．7％。结论：在乳酸乳球菌细胞内表达的重组TGEV S蛋白获得了理想表达,为进一步研制开发防治TGE口服疫苗提供物质基础。     

食品级乳酸乳球菌pNZ8149-luc质粒的构建及表达

目的:构建能够稳定表达萤火虫荧光素酶报告基因(luc)的乳酸乳球菌(Lactococcus lactis, L.lactis)食品级表达系统,以便后续研究对目的基因进行示踪。方法:从pGL4.10质粒中PCR扩增萤火虫荧光素酶报告基因,测序,克隆至载体pNZ8149,构建pNZ8149-luc表达质粒;电击转化宿主乳酸乳球菌NZ3900,采用乳糖筛选法获得重组的乳酸乳球菌,Nisin诱导,采用微孔板发光检测仪检测荧光素酶的存在,Western Blot检测目标蛋白luc的表达。结果:PCR扩增的荧光素酶报告基因成功克隆至pNZ8149质粒,并电击转化宿主乳酸乳球菌NZ3900,得到乳酸乳球菌表达系统NZ3900/pNZ8149-luc。Nisin诱导后,检测到荧光素酶随诱导时间的延长活性逐渐增强,时间超过24 h之后荧光素酶活性逐渐下降。Western Blot检测到目标蛋白luc在胞内表达。结论:成功构建了p NZ8149-luc表达载体,并能够在乳酸乳球菌体内稳定表达。     

表达空肠弯曲菌CfrA蛋白重组乳酸乳球菌的构建及其免疫效果北大核心CSCD

【目的】本试验将空肠弯曲菌肠菌素受体蛋白CfrA编码基因导入食品级乳酸乳球菌表达系统,然后将重组乳酸乳球菌口服免疫鸡,降低空肠弯曲菌在鸡肠道中的定殖。【方法】利用PCR分别扩增空肠弯曲菌cfrA全基因及其N端片段,插入食品级表达载体pNZ8149多克隆位点并转化乳酸乳球菌NZ3900,通过Western blot鉴定重组菌株CfrA蛋白表达情况,同时通过筛选nisin浓度、温度、时间等诱导条件优化重组蛋白表达水平;进而将重组乳酸乳球菌经口服免疫SPF鸡,免疫后分别测定乳酸乳球菌自鸡体内的排出情况、以及诱导CfrA血清抗体和粘膜抗体水平,最后将空肠弯曲菌口服攻毒免疫后的鸡,通过测定鸡泄殖腔棉拭子中空肠弯曲菌的数目来判定口服免疫效果。【结果】Western blot检测显示CfrA全基因及其N端片段均可在重组乳酸乳球菌胞内可溶性表达,不分泌,筛选的最佳诱导表达条件为nisin浓度25 ng/mL、温度37°C、时间1 h。口服乳酸乳球菌10 d内自鸡体完全排空;鸡口服免疫后可产生CfrA蛋白特异性的血清IgG和肠粘膜sIgA抗体;重组乳酸乳球菌口服免疫后空肠弯曲菌在鸡体内的增殖速度显著低于对照组。【结论】成功构建了重组CfrA蛋白的食品级乳酸乳球菌诱导表达系统;表达CfrA蛋白的重组乳酸乳球菌口服免疫鸡对空肠弯曲菌在鸡肠道的定殖具有一定的抑制作用,为研制重组乳酸菌口服家禽免疫制剂防治空肠弯曲菌奠定了基础。     

重组乳酸乳球菌表达禽流感病毒HA1基因载体的构建及在禽流感病毒防治领域的应用

目的构建以重组乳酸乳球菌为基础的黏膜输送载体。方法以高致病性禽流感病毒H5N1的HA1基因作为研究对象,利用nisin诱导表达控制系统,构建分泌型与非分泌型重组乳酸乳球菌表达载体,经口服灌胃途径免疫BALB/c小鼠,通过ELISA检测小鼠血清IgG和粪便IgA,最后,对免疫后的小鼠进行H5N1病毒攻击实验,进而比较分泌型与非分泌型重组乳酸乳球菌表达载体的免疫效率。结果分泌型重组乳酸乳球菌免疫小鼠后产生的抗体水平（IgG和IgA）高于非分泌型重组乳酸乳球菌,经过同型H5N1病毒攻击后,分泌型重组乳酸乳球菌免疫的小鼠的存活率为80%,而非分泌型重组乳酸乳球菌免疫的小鼠的存活率为60%。结论本研究为防治高致病性禽流感病毒提供可行的思路与方法。     

抗艰难梭菌毒素纳米抗体在乳酸乳球菌中重组表达及其功能分析

本研究旨在构建表达抗艰难梭菌毒素的纳米抗体重组乳酸乳球菌。所述的抗体为免疫羊驼后从外周血中分离的天然缺失轻链的纳米抗体(分别命名为E3、AA6)。构建重组质粒pNZ8148-E3-AA6,转化乳酸乳球菌NZ9000后诱导表达,SDSPAGE及Western blot检测到32 kD的目的蛋白。利用镍柱亲和层析法纯化重组蛋白E3-AA6,BCA试剂盒测定其浓度。通过细胞变圆实验以及CCK8实验鉴定其功能,E3-AA6能够抑制艰难梭菌毒素TcdB的毒性。本实验成功构建了重组表达载体pNZ8148-E3-AA6,通过NICE系统实现了二价抗体的表达,为治疗艰难梭菌引发的感染提供了新的治疗途径。     

使用偏爱密码子大幅度提高苯丙氨酸脱氨酶在食品级乳酸乳球菌中的表达

为获得苯丙氨酸脱氨酶(PAL)在食品级乳酸乳球菌中的高效表达,将欧芹palcDNA(palnat)及根据乳酸乳球菌偏爱密码子设计人工合成的pal基因(palart)重组并转化到两种乳酸乳球菌NICE诱导表达系统中,测定基因工程菌表达PAL酶的量及活性,对比分析密码子偏爱性对乳酸乳球菌表达外源蛋白的影响。结果表明在两种乳酸乳球菌NICE表达系统中,使用偏爱密码子均可显著提高PAL酶的表达效率,使NZ9000/pNZ8048表达系统表达量提高22.23倍,NZ3900/pNZ8149系统提高35.90倍。此研究获得了安全高效表达PAL,可用于治疗苯丙酮尿症的基因工程菌。     

在乳酸乳球菌中表达外源谷氨酰胺转胺酶显著改善宿主菌好氧生长性能

为改善乳酸乳球菌的生长性能,以轮枝链霉菌染色体DNA为模板,扩增得到编码谷氨酰胺转胺酶成熟酶的基因mtg,将其克隆到质粒pNZ8148中,电转化乳酸乳球菌NZ9000,获得乳酸乳球菌NZ9000(pFL001)(重组菌)。在不控制pH条件下,重组菌的胞外pH显著高于对照菌NZ9000(pNZ8148);前者的最高生物量可达4.13gL,而后者只有0.34gL。在控制pH为6.5±0.1的条件下,重组菌最高生物量为4.73gL,对葡萄糖的菌体最高平均得率为71.1gmol,而相同条件下对照菌最高生物量为2.6gL,对葡萄糖的菌体最高平均得率为27.3gmol。由此表明,重组菌与对照菌相比,好氧生长性能得到显著改善。可能的原因是mtg的活性表达升高了重组菌的胞内pH,原先用于泵出胞内H 所需的部分能量可能因此得到节省,这样相应增加了用于细胞生长的能量。     

乳酸乳球菌表面表达Brazzein甜味蛋白系统的建立

参照甜味蛋白Brazzein基因序列,结合乳酸乳球菌的密码子偏嗜性的相关分析,对甜味蛋白Brazzein基因进行改造,将第29位天冬氨酸、31位的组氨酸和第41位的谷氨酸分别突变为赖氨酸、丙氨酸和赖氨酸,以期提高目的蛋白的甜度。采用重叠PCR的方法合成目的基因,目的片段亚克隆到pMD18-T载体上。经序列测定分析后,目的片段克隆入分泌表达载体pNZ8112,电转化乳酸乳球菌中,构建成表面展示表达甜味蛋白Brazzein的乳酸乳球菌表达系统。     

谷胱甘肽在乳酸乳球菌抵抗氧胁迫中的保护作用

为研究谷胱甘肽(GSH)在乳酸乳球菌NZ9000抗氧胁迫中的生理作用,以能够生物合成GSH的重组菌NZ9000(pNZ3203)为实验菌株进行了研究。结果表明,在较高H2O2胁迫剂量(150mmol/L H2O2,15min)下,前培养3h、5h和7h(即乳酸链球菌素诱导1h、3h和5h)时的重组菌细胞的存活率分别是处于相应生长时期对照菌NZ9000(pNZ8148)的1.8±0.1倍、2.6±0.1倍和2.9±0.3倍。表明GSH可以提高宿主菌NZ9000对H2O2所引发氧胁迫的抗性。GSH还可以提高宿主菌NZ9000对其它化学物质(如超氧阴离子自由基生成剂———甲萘醌)所引发氧胁迫的抗性。这表现在经20mmol/L甲萘醌处理60min后,前培养5h(即乳酸链球菌素诱导3h)时重组菌细胞的存活率是对照菌的6.2±0.1倍。由此表明,通过代谢工程手段在菌株NZ9000中引入GSH合成能力,可以提高宿主菌对氧胁迫的抗性。     

牛凝乳酶原基因在乳酸乳球菌中的表达

【目的】利用乳酸乳球菌nisin诱导基因表达系统(the NIsin Controlled gene Expression system,NICE)表达牛凝乳酶原。【方法】从克隆载体pS19-PPC中获得牛凝乳酶原基因,将该基因与表达载体pNZ8148连接并电转化乳酸乳球菌NZ9000,转化子经酶切、PCR和测序鉴定后,用nisin进行诱导表达,表达产物利用SDS-PAGE和Western blot鉴定,表达产物纯化后检测凝乳活性。【结果】重组牛凝乳酶原与天然牛凝乳酶原比较,其分子量大小、免疫性质、生物活性和抑制剂敏感性没有发现显著差异,其凝乳活性可达2×103IMCU/mL。【结论】在乳酸乳球菌中表达了具有凝乳活性的牛凝乳酶原,同时乳酸乳球菌作为发酵剂和凝乳酶产生菌双重角色的实现,为奶酪加工提供了新思路和新方法。     

Introducing glutathione biosynthetic capability into Lactococcus lactis subsp. cremoris NZ9000 improves the oxidative-stress resistance of the host

This study describes how a metabolic engineering approach can be used to improve bacterial stress resistance. Some Lactococcus lactis strains are capable of taking up glutathione, and the imported glutathione protects this organism against H(2)O(2)-induced oxidative stress. L. lactis subsp. cremoris NZ9000, a model organism of this species that is widely used in the study of metabolic engineering, can neither synthesize nor take up glutathione. The study described here aimed to improve the oxidative-stress resistance of strain NZ9000 by introducing a glutathione biosynthetic capability. We show that the glutathione produced by strain NZ9000 conferred stronger resistance on the host following exposure to H(2)O(2) (150 mM) and a superoxide generator, menadione (30 microM). To explore whether glutathione can complement the existing oxidative-stress defense systems, we constructed a superoxide dismutase deficient mutant of strain NZ9000, designated as NZ4504, which is more sensitive to oxidative stress, and introduced the glutathione biosynthetic capability into this strain. Glutathione produced by strain NZ4504(pNZ3203) significantly shortens the lag phase of the host when grown aerobically, especially in the presence of menadione. In addition, cells of NZ4504(pNZ3203) capable of producing glutathione restored the resistance of the host to H(2)O(2)-induced oxidative stress, back to the wild-type level. We conclude that the resistance of L. lactis subsp. cremoris NZ9000 to oxidative stress can be increased in engineered cells with glutathione producing capability.     

乳酸乳球菌食品级诱导表达系统的构建及异源蛋白的表达

以α-aga基因为食品级选择标记构建了乳酸乳球菌食品级高效诱导细胞内和细胞壁锚定表达系统,并用这一表达系统表达了铜绿假单胞菌融合外膜蛋白基因OprF/H。首先以pRAF800和pNZ8048构建了含有α-aga、PnisA-MCS-TpepN和θ复制子的乳酸乳球菌食品级细胞内诱导表达载体pRNA48,再以pRNA48和pVE5524为出发载体构建了含有α-aga、PnisA-SPUsp45-nucA-CWAM6-t1t2和θ复制子的乳酸乳球菌细胞壁锚定诱导表达载体pRNV48。然后以食品级载体pRNA48和pRNV48为基础,构建了不含抗生素抗性选择标记的铜绿假单胞菌融合外膜蛋白基因的表达质粒pRNA48-OprF/H和pRNV48-OprF/H。利用nisin进行重组乳酸乳球菌菌株的诱导表达,通过SDS-PAGE和Western blot分析,检测到表达蛋白分别占细胞内可溶蛋白的9.6%和细胞壁锚定蛋白的9.8%,表达产物具有免疫原性,可与含OprF/H的乳球菌以及铜绿假单胞菌发生特异性的凝集反应。     

硬脂酰-辅酶A脱氢酶基因在食品级乳酸菌中的表达

为了实现硬脂酰-辅酶A脱氢酶1编码基因在乳酸乳球菌中的表达,采用PCR技术扩增获得人类scd1的编码序列。Nco I和Xba I双酶切后定向插入到食品级表达载体pNZ8149中,构建表达载体pNZ8149-scd1。电转化乳酸乳球菌NZ3900,经菌落PCR和测序鉴定scd1基因成功插入到乳酸乳球菌中。在乳链菌肽诱导下进行scd1的表达,转化株提取脂肪酸,进行脂肪酸含量的气相色谱分析。结果显示,SCD1转化菌株中的C16∶1n-7和C18∶1n-7脂肪酸组分比转化pNZ8149的对照组乳酸菌分别提高了92%~169%和53%~127%。文中以scd1基因为例,尝试并证明了脂肪酸脱氢酶类基因能够在食品级乳酸菌中有效表达,为后续研究奠定了基础。     

Gene cloning, functional expression and secretion of the S-layer protein SgsE from Geobacillus stearothermophilus NRS 2004/3a in Lactococcus lactis

The ~93-kDa surface layer protein SgsE of Geobacillus stearothermophilus NRS 2004/3a forms a regular crystalline array providing a nanopatterned matrix for the future display of biologically relevant molecules. Lactococcus lactis NZ9000 was established as a safe expression host for the controlled targeted production of SgsE based on the broad host-range plasmid pNZ124Sph, into which the nisA promoter was introduced. SgsE devoid of its signal peptide-encoding sequence was cloned into the new vector and purified from the cytoplasm at a yield of 220 mg l- of expression culture. Secretion constructs were based on the signal peptide of the Lactobacillus brevis SlpA protein or the L. lactis Usp45 protein, allowing isolation of 95 mg of secreted rSgsE l-1. N-terminal sequencing confirmed correct processing of SgsE in L. lactis NZ9000. The ability of rSgsE to self-assemble in suspension and to recrystallize on solid supports was demonstrated by electron and atomic force microscopy.     

幽门螺杆菌napA基因在乳酸菌中的表达及免疫原性分析

为在乳酸菌中表达幽门螺杆菌（Helicobacter pylori,H.pylori）中性粒细胞激活蛋白(NAP),口服免疫小鼠后检测其免疫原性。在实验中利用了分子克隆技术构建携带nap基因的重组原核表达质粒pNICE:secnap,将重组质粒转化乳酸菌NZ9000株,筛选鉴定阳性菌落,诱导表达的NAP蛋白用SDSPAGE和Western blot进行鉴定。将雌性ICR（CV级）小鼠随机分为4组,分别用PBS、携带空质粒的乳酸菌、携带pNICE:secnap的乳酸菌、灭活的H.pylori 灌胃。免疫7次后检测其特异性IgG和IgA的产生。成功扩增了nap基因并构建了重组原核表达质粒pNICE:secnap,转化乳酸菌NZ9000后经nisin诱导可表达Mr约17kDa的重组蛋白,表达量约占菌体总蛋白量的9.5%,表达的蛋白能与兔抗H.pylori 血清特异性反应,具有良好的免疫原性。携带pNICE:secnap质粒的乳酸菌刺激产生的IgG水平明显高于携带空质粒组,与灭活H.pylori组没有明显的差异,但其刺激产生的IgA水平明显高于其他组。以上结果说明表达NAP蛋白的乳酸菌口服免疫小鼠后,能够刺激小鼠产生特异的IgG和IgA,对幽门螺杆菌疫苗的研究开发具有理论意义。为乳酸菌作为抗原递送载体的研究和H.pylori口服疫苗的开发提供了一定的实验基础。     

Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae

Lactococcus lactis NZ9000 is a non-pathogenic non-invasive bacterium extensively used for the delivery of antigens and cytokines at the mucosal level. However, there are no reports concerning the per se immunomodulatory capacity of this strain. The aim of the present study was to investigate the intrinsic immunostimulating properties of the nasal administration of L. lactis NZ9000 in a pneumococcal infection model. Mice were preventively treated with L. lactis (2, 5 or 7 days with 10(8) cells/day per mouse) and then challenged with Streptococcus pneumoniae. The local and the systemic immune responses were evaluated. Our results showed that nasal administration of L. lactis for 5 days (LLN5d) increased the clearance rate of S. pneumoniae from lung and prevented the dissemination of pneumococci into blood. This effect coincided with an upregulation of the innate and specific immune responses in both local and systemic compartments. LLN5d increased phagocyte activation in lung, blood and bone marrow, determined by NBT and peroxidase tests. Anti-pneumococcal immunoglobulin (Ig)A in bronchoalveolar lavages (BAL) and IgG in BAL and serum were increased in the LLN5d group. Lung tissue injury was reduced by LLN5d treatment as revealed by histopathological examination and albumin concentration and lactate dehydrogenase activity in BAL. The adjuvant effect of L. lactis in our infection model would be an important advantage for its use as a delivery vehicle of pneumococcal proteins and nasal immunization with recombinant L. lactis emerges as an effective route of vaccination for both systemic and mucosal immunity against pneumococcal infection.